Kidney structures and methods of forming the same

US9580688B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9580688-B2
Application numberUS-61833809-A
CountryUS
Kind codeB2
Filing dateNov 13, 2009
Priority dateJun 8, 2007
Publication dateFeb 28, 2017
Grant dateFeb 28, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro, and methods of use thereof. The cells may be provided in a three dimensional matrix for culturing in vitro and/or implanting in vivo. Methods of seeding cells onto the matrix are also provided.

First claim

Opening claim text (preview).

That which is claimed is: 1. A method of treating a kidney disease in a patient in need thereof, said method comprising: providing a composition comprising an isolated population of differentiated mammalian kidney cells comprising peritubular interstitial cells, wherein said cells are harvested from differentiated cells of a mammalian kidney tissue, passaged in vitro from 2 to 9 times, and seeded onto a three dimensional matrix, wherein (i) the cells of said population produce erythropoietin (EPO) under normoxic conditions, and (ii) the differentiated cells of the mammalian kidney tissue or the population of cells have not been manipulated by the introduction of an exogenous gene that stimulates the production of EPO or by an exogenous chemical that stimulates the production of EPO; and administering said composition to said patient in an amount effective to treat said kidney disease by surgically implanting said composition subcutaneously or into the kidney of said patient, to thereby treat said kidney disease in said patient in need thereof. 2. The method of claim 1 , wherein said cells are positive for a marker selected from the group consisting of: neprilysin (NEP), Tamm-Horsfall protein (THP), podocin (POD), and combinations thereof, after said passaging. 3. The method of claim 1 , wherein said population consists essentially of said differentiated mammalian kidney cells. 4. The method of claim 1 , subject to the proviso that said cells are not transfected with an exogenous DNA encoding a polypeptide. 5. The method of claim 1 , wherein said cells are human. 6. The method of claim 1 , wherein said matrix comprises neutralized collagen type I. 7. The method of claim 1 , wherein said kidney disease is an anemia selected from the group consisting of: an anemia of renal failure, an anemia of end-stage renal disease, an anemia of a chemotherapy, an anemia of a radiation therapy, an anemia of chronic infection, an anemia of an autoimmune disease, an anemia of rheumatoid arthritis, an anemia of AIDS, an anemia of a malignancy, an anemia of prematurity, an anemia of hypothyroidism, an anemia of malnutrition, and an anemia of a blood disorder. 8. The method of claim 7 , wherein said anemia is an anemia of renal failure. 9. The method of claim 7 , wherein said anemia is an anemia of end-stage renal disease. 10. The method of claim 1 , wherein the matrix comprises a gel. 11. The method of claim 10 , wherein the gel is a hydrogel. 12. The method of claim 10 , wherein the gel is solidified. 13. The method of claim 1 , wherein at least 40% or more of the cells of said population produce erythropoietin (EPO). 14. The method of claim 1 , wherein at least 20% or more of the cells of said population produce erythropoietin (EPO). 15. The method of claim 1 , wherein said kidney disease results in decreased EPO production in a patient, and wherein said cells produce EPO in vivo. 16. The method of claim 1 , wherein said cells are syngeneic with respect to the patient. 17. The method of claim 1 , wherein said cells are autogeneic with respect to the patient. 18. The method of claim 1 , wherein the three dimensional matrix is biodegradable, and the population is provided in a treatment-effective amount. 19. The method of claim 1 , wherein said differentiated mammalian kidney cells have been passaged in vitro from 2 to 6 times.

Assignees

Inventors

Classifications

  • of the kidneys · CPC title

  • Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

  • Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland · CPC title

  • C12N5/0686Primary

    Kidney cells · CPC title

  • Atmosphere, e.g. low oxygen conditions · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9580688B2 cover?
Provided herein are isolated populations of kidney cells harvested from differentiated cells of the kidney, wherein cells have been expanded in vitro, and methods of use thereof. The cells may be provided in a three dimensional matrix for culturing in vitro and/or implanting in vivo. Methods of seeding cells onto the matrix are also provided.
Who is the assignee on this patent?
Atala Anthony, Yoo James J, Univ Wake Forest Health Sciences
What technology area does this patent fall under?
Primary CPC classification C12N5/0686. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Feb 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).